Evidence map›Paper›PMID 42105274›Full record

ArticleClinical and translational science2026

Effects of a High-Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia.

Hengbang Wang, Yun Yang, Zi Chen, Min Yu, Lixin Jiang, Lichuang Men, Hua Yan, Dajun Yang, Yifan Zhai

Abstract readClinical Trial, Phase I
In one paragraph

Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hengbang WangGuangzhou Healthquest Pharma Co. Ltd., Guangzhou, China.ORCID 0000-0003-3740-9056
Yun YangGuangzhou Healthquest Pharma Co. Ltd., Guangzhou, China.ORCID 0009-0001-4999-6975
Zi ChenGuangzhou Healthquest Pharma Co. Ltd., Guangzhou, China.ORCID 0009-0007-9586-2867
Min YuGuangzhou Healthquest Pharma Co. Ltd., Guangzhou, China.ORCID 0009-0006-7768-5249
Lixin JiangAscentage Pharma Group Inc., Rockville, Maryland, USA.ORCID 0009-0006-8614-142X
Lichuang MenGuangzhou Healthquest Pharma Co. Ltd., Guangzhou, China.ORCID 0009-0007-5530-7869
Hua YanGuangzhou Healthquest Pharma Co. Ltd., Guangzhou, China.ORCID 0009-0007-7634-7712
Dajun YangGuangzhou Healthquest Pharma Co. Ltd., Guangzhou, China.ORCID 0000-0002-6027-3604
Yifan ZhaiGuangzhou Healthquest Pharma Co. Ltd., Guangzhou, China.ORCID 0000-0003-1672-2262

Funding

Guangzhou Healthquest Pharma Co. Ltd
6 · The paper itself

Abstract

Olverembatinib is approved in China to treat patients with chronic- or accelerated-phase chronic myeloid leukemia (CML-CP or CML-AP) with T315I mutations and CML-CP that is resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors. The objective of this study was to determine the effects of a high-fat meal on the pharmacokinetics of olverembatinib in patients with CML. Twelve participants were enrolled and received olverembatinib treatment over two periods, with a washout of 7 days between consecutive doses. Pharmacokinetics and safety were assessed in all participants. When olverembatinib was administered with a high-fat meal, the maximum plasma concentration (C

Indexed as

Diet, High-FatFood-Drug InteractionsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsAdultAgedArea Under CurveFemaleHalf-LifeHumansMaleMiddle AgedProtein Kinase InhibitorsBCR::ABL1 tyrosine kinase inhibitor (TKI)chronic myeloid leukemia (CML)food effect

Identifiers

PMID42105274
PMCPMC13157130

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.